KCM
LGND icon

Kennedy Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Kennedy Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33,853
Closed -$2.42M – 753
2023
Q4 		$2.42M Sell
33,853
-1,846
-5% -$109K 0.05% 452
2023
Q3 		$2.14M Buy
35,699
+1,215
+4% +$80K 0.05% 447
2023
Q2 		$2.49M Buy
34,484
+19,815
+135% +$1.49M 0.06% 419
2023
Q1 		$1.08M Buy
14,669
+3,422
+30% +$243K 0.03% 478
2022
Q4 		$751K Sell
11,247
-6,803
-38% -$442K 0.02% 518
2022
Q3 		$970K Buy
18,050
+2
+0% +$118 0.03% 485
2022
Q2 		$1M Buy
18,048
+880
+5% +$49.9K 0.03% 473
2022
Q1 		$1.21M Sell
17,168
-168
-1% -$12.2K 0.03% 479
2021
Q4 		$1.67M Sell
17,336
-605
-3% -$55.9K 0.04% 468
2021
Q3 		$1.56M Sell
17,941
-1,074
-6% -$83.1K 0.03% 486
2021
Q2 		$1.56M Sell
19,015
-4,945
-21% -$411K 0.03% 499
2021
Q1 		$2.28M Sell
23,960
-152,517
-86% -$14.4M 0.05% 503
2020
Q4 		$10.9M Buy
176,477
+85,431
+94% +$4.87M 0.25% 126
2020
Q3 		$5.41M Sell
91,046
-158,313
-63% -$10.8M 0.16% 244
2020
Q2 		$17.4M Sell
249,359
-11,659
-4% -$739K 0.5% 19
2020
Q1 		$11.8M Buy
261,018
+148,625
+132% +$8.42M 0.44% 22
2019
Q4 		$7.31M Buy
112,393
+20,578
+22% +$1.38M 0.18% 199
2019
Q3 		$5.7M Buy
91,815
+65,795
+253% +$4.13M 0.14% 275
2019
Q2 		$1.85M Sell
26,020
-48,164
-65% -$3.55M 0.04% 547
2019
Q1 		$5.82M Buy
74,184
+55,875
+305% +$4.23M 0.14% 282
2018
Q4 		$1.55M Sell
18,309
-57,798
-76% -$6.16M 0.04% 564
2018
Q3 		$13M Buy
76,107
+1,468
+2% +$221K 0.24% 111
2018
Q2 		$9.65M Buy
74,639
+1,638
+2% +$183K 0.18% 174
2018
Q1 		$7.52M Sell
73,001
-1,290
-2% -$128K 0.15% 244
2017
Q4 		$6.35M Sell
74,291
-341
-0.5% -$29.6K 0.11% 329
2017
Q3 		$6.34M Buy
+74,632
New +$5.91M 0.11% 317

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's LGND Position: Q1 2024 in Review

Kennedy Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2024, closing a stake of 33,853 shares — an estimated $2.42M sold.

Kennedy Capital Management first reported a position in LGND in Q3 2017 and held it in 26 quarters. The position peaked at $17.4M in Q2 2020. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

  • Kennedy Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 33,853 Ligand Pharmaceuticals shares in Q1 2024, an estimated $2.42M.
  • Kennedy Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 26 quarters.
  • Kennedy Capital Management's Ligand Pharmaceuticals position peaked at $17.4M in Q2 2020.
  • 222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on Kennedy Capital Management's 13F filing for Q1 2024, filed 15 May 2024.